Does GHI Cover Wegovy? Exclusions, Covered GLP-1s, and Appeals

GHI does not cover Wegovy when it is prescribed for weight loss. The drug is left off the GHI PPO formulary administered by EmblemHealth, and New York City has said it never intended to cover GLP-1 medications for weight management under its municipal employee plans. A narrow opening may exist when Wegovy is prescribed to reduce cardiovascular risk, but that pathway is not spelled out in the plan documents and has to be pursued directly with EmblemHealth.

Why Wegovy Is Excluded

Wegovy (semaglutide) does not appear on the 2025 or 2026 GHI PPO Preferred Plan Base Benefit Formulary.1EmblemHealth. PPO City of New York Base Formulary 2025 The base formulary is defined by what it includes, not by a long exclusion list, and it covers only a narrow set of prescription categories: diabetes medications, treatments for substance use disorders, and preventive medications required under the Affordable Care Act. Weight-loss drugs fall outside all of those buckets.

EmblemHealth’s pharmacy policy on GLP-1 agonists goes further. It states that Wegovy, Saxenda, and Zepbound “are not indicated for the treatment of diabetes and are not targeted in this policy,” and that coverage for weight loss treatment is “not recommended.”2EmblemHealth. Diabetes – Glucagon-Like Peptide-1 Agonists Pharmacy Policy The policy draws a hard line between semaglutide for type 2 diabetes (sold as Ozempic) and semaglutide for chronic weight management (sold as Wegovy). Only the diabetes version is on the covered side of that line. The GHI CBP Summary of Benefits and Coverage separately lists “weight loss programs” among services the plan generally does not cover.3NYC Office of Labor Relations. SBC – GHI CBP Basic and Enhanced With Rx

The 2024 Coverage That Was Cut Off in 2025

If you had Wegovy or Zepbound covered through your city plan and then lost it, that was not your imagination. In early 2024, nearly 1,000 New York City workers and dependents began receiving coverage for GLP-1 weight-loss injectables through EmblemHealth. City spokesperson Liz Garcia later told reporters the coverage had been granted “in error” and that the city “never planned to cover these drugs” because of their cost.4Futurism. NYC Insurance GLP-1 Coverage Error

Affected employees were told by letter that coverage for GLP-1 drugs used strictly for weight loss would end in January 2025. People already on the medications were grandfathered through June 2025 or the end of their existing prior authorization, whichever came first.5Yahoo News. New York City Insurance GLP-1 Coverage Reversal Coverage for GLP-1 drugs prescribed for diabetes was not touched.

The Cardiovascular Indication: A Possible Opening

In March 2024 the FDA approved Wegovy for a second use: reducing the risk of major adverse cardiovascular events, meaning heart attack, stroke, and cardiovascular death, in adults with established cardiovascular disease who are also obese or overweight.6U.S. Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults With Obesity or Overweight That approval opened a question that GHI’s documents do not resolve.

As of mid-2026, EmblemHealth’s formulary and GLP-1 policy do not address a cardiovascular pathway for Wegovy. The authorization criteria in the clinical policy are limited to type 2 diabetes, and the formulary does not list cardiovascular risk reduction as a basis for approving Wegovy or similar drugs.2EmblemHealth. Diabetes – Glucagon-Like Peptide-1 Agonists Pharmacy Policy If your doctor believes Wegovy is medically necessary to reduce your cardiovascular risk, the only route is to call EmblemHealth and ask whether the plan’s general medical-necessity standard can apply. The GHI PPO formulary lists customer service at 212-501-4444 for these inquiries.1EmblemHealth. PPO City of New York Base Formulary 2025

Which GLP-1 Drugs GHI Does Cover

Several GLP-1 medications are on the GHI formulary, but all of them require a type 2 diabetes diagnosis along with prior authorization and quantity limits. Covered options include Ozempic (injectable semaglutide at a lower dose than Wegovy), Mounjaro (tirzepatide), Trulicity (dulaglutide), Rybelsus (oral semaglutide), and generic exenatide and liraglutide.1EmblemHealth. PPO City of New York Base Formulary 2025 They sit under “Non-Insulin Hypoglycemic Agents.” The EmblemHealth policy explicitly warns that these diabetes GLP-1s are not approved for weight loss in people who do not have type 2 diabetes.2EmblemHealth. Diabetes – Glucagon-Like Peptide-1 Agonists Pharmacy Policy A doctor cannot simply write Ozempic for weight loss and expect the plan to pay.

Medicare and Medicaid Through EmblemHealth

If your coverage is through an EmblemHealth Medicare Part D plan rather than active-employee GHI, the baseline answer is the same: standard Part D does not cover Wegovy for weight management. CMS has said Part D plans are not responsible for covering Wegovy when it is prescribed solely for weight reduction. Part D plans may cover Wegovy when it is prescribed specifically to reduce cardiovascular risk in adults with established cardiovascular disease who are also obese or overweight.7Centers for Medicare & Medicaid Services. Information for Part D Plans – Medicare GLP-1 Bridge

For weight management specifically, CMS launched the Medicare GLP-1 Bridge, a demonstration that runs from July 2026 through December 2027 and operates outside the normal Part D benefit. It is managed by a single central processor, Humana, not by individual Part D sponsors like EmblemHealth. CMS encourages plans that receive a prior authorization request for a weight-loss GLP-1 to direct the provider to the Bridge program.7Centers for Medicare & Medicaid Services. Information for Part D Plans – Medicare GLP-1 Bridge

New York State Medicaid also does not cover GLP-1 drugs for weight management. A rare exception applies for secondary cardiovascular prevention, requiring a BMI of 40 or above and documented atherosclerotic cardiovascular disease.8Navigate Weight MD. A Practical Guide to GLP-1 Prior Authorizations 2026

How to Confirm Your Coverage and Appeal a Denial

EmblemHealth administers many plan configurations under the GHI name, so it is worth confirming the answer for your exact plan before assuming anything.

  • Use the Prime Therapeutics drug lookup tool from EmblemHealth’s pharmacy portal. Select your specific plan type for an accurate result.9EmblemHealth. Pharmacy Resources
  • Check the formulary name or letter printed on the front of your member ID card and match it to the drug list on EmblemHealth’s website.10EmblemHealth. Drugs Covered
  • Call the customer service number on your member ID card.
  • If you are on Medicare, use EmblemHealth’s Medicare formulary and cost calculator or call the Medicare Connect Concierge at 877-344-7364.11EmblemHealth. Formularies and Rx Cost Calculator

If a request is denied, Medicare members can file an appeal, called a redetermination, using the Medicare Prescription Drug Coverage Redetermination Request Form. The prescribing doctor has to document why the drug is medically necessary and why formulary alternatives would not work. Standard appeals are decided within 30 calendar days; expedited appeals are decided within 72 hours when a doctor certifies that the standard timeline could seriously jeopardize the member’s health.12EmblemHealth. Medicare Grievances and Appeals For non-Medicare GHI plans, call customer service to start the appeal process; the Summary of Benefits points members to the full plan document for the detailed exception rules.